Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-03-26 Earnings Release
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement
Earnings Release Classification · 100% confidence The document is titled "OSE Immunotherapeutics publie ses résultats financiers annuels 2024..." (OSE Immunotherapeutics publishes its annual financial results 2024...). It explicitly details the financial results for the year ending December 31, 2024, including a table showing consolidated annual figures (Résultat net, Résultat opérationnel courant, Total bilan consolidé) as of 31/12/2024 and 31/12/2023. The text confirms that the Board of Directors approved the annual consolidated accounts established under IFRS as of December 31, 2024. This content strongly indicates a comprehensive annual financial report, which aligns with the definition of a 10-K, even though the document is presented in French and might be a local equivalent or a press release accompanying the formal filing. Given the depth of the annual financial data presented, it is classified as the Annual Report (10-K) rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). FY 2024
2025-03-26 French
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Earnings Release Classification · 100% confidence The document is explicitly titled "OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update" and contains detailed consolidated annual financial statements for the year ended December 31, 2024, including a P&L table and balance sheet figures. It mentions that the Board approved the annual and consolidated financial statements prepared under IFRS as of December 31, 2024. This content strongly indicates a comprehensive annual financial report. Although it is an announcement, the document itself contains the core financial data and is structured like a full annual report summary, rather than just a brief notice of publication (RPA). Given the comprehensive nature of the financial data presented for the full year, it aligns best with the Annual Report category (10-K), even if the company is European and might file a different regulatory document in its home jurisdiction. In the context of the provided definitions, 'Annual Report (Code: 10-K)' is the closest fit for a full-year financial results disclosure. FY 2024
2025-03-26 English
OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé
Earnings Release Classification · 95% confidence The document is a press release dated March 11, 2025, announcing positive preliminary clinical trial results for the drug OSE2101 (Tedopi®) in advanced pancreatic cancer. It details the trial's primary endpoint achievement, mentions that more detailed results will be presented at a future medical congress, and includes quotes from the Principal Investigator and the CEO. This content structure—announcing key clinical/financial milestones immediately—is characteristic of an Earnings Release (ER) or a general press release regarding operational updates. Since it focuses specifically on the immediate release of key clinical trial results (not a full financial report like 10-K or IR, nor a transcript of a call), the most appropriate classification is Earnings Release (ER), as these often include operational/clinical highlights. It is not a Call Transcript (CT) because it is a written announcement, not a Q&A session transcript. It is not an Interim Report (IR) as it focuses on a specific trial result, not comprehensive period financials. It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available. Q1 2025
2025-03-11 French
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
Earnings Release Classification · 95% confidence The document is a press release announcing positive topline results from a Phase 2 clinical trial (TEDOPaM) for a drug called OSE2101 (Tedopi®) in pancreatic cancer. It details the trial's primary endpoint achievement, quotes the CEO and Principal Investigator, and provides background information on the disease and the involved entities (OSE Immunotherapeutics and GERCOR). This format—a news announcement of key clinical or operational milestones, often including financial/operational highlights but not being the full periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is specifically announcing the results of a clinical trial, it functions as a major operational update that would typically accompany or precede a formal financial filing. Given the options, it most closely aligns with an Earnings Release (ER) which covers key operational/financial highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, the content is a direct announcement of positive trial results, which is a key performance indicator often highlighted in an ER. Since it is not a full report (10-K, IR) and not explicitly a proxy/dividend/management change notice, ER is the best fit for a major operational/clinical result announcement. FY 2023
2025-03-11 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital" (Information relating to the total number of voting rights and shares comprising the capital). It explicitly states that it is published in application of the French Commercial Code (Article L. 233-8 II) and AMF General Regulation (Article 223-16). It provides a table detailing the total number of shares and voting rights as of February 28, 2025. This content directly relates to the official disclosure of share capital structure and voting rights, which aligns best with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), although it is a periodic update rather than a result of a specific vote. Given the options, DVA is the most specific fit for capital/voting rights disclosure, although 'Regulatory Filings' (RNS) could also apply if DVA were not available. Since the core content is the official count of voting rights, DVA is selected.
2025-03-06 French
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
Regulatory Filings Classification · 99% confidence The document is a press release dated March 6, 2025, announcing that OSE Immunotherapeutics hosted a KOL Webinar post-ECCO regarding Lusvertikimab. It details the speakers and the topics discussed, and crucially, it provides a link to the FULL WEBINAR VIDEO. This format—an announcement about an event (a webinar) that has already occurred, often including forward-looking statements and contact information—is characteristic of a general corporate communication or press release. Since the content is a discussion/presentation summary rather than a formal financial report (like 10-K, IR, ER) or a specific regulatory filing about transactions (like DIRS, POS), it fits best under the general category for corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially an Investor Presentation (IP) if it were the slides themselves. Given it's a summary of a hosted event/webinar, RNS is the most appropriate general classification for this type of corporate news release that isn't a core financial filing or a specific event material like AGM-R or IP.
2025-03-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.